Memo Therapeutics and Ono Pharmaceutical enter partnership

Under the terms of the agreement, Memo Therapeutics AG will leverage its microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at highest speed, efficiency, and sensitivity for immuno-oncology targets. Ono will acquire intellectual property rights and worldwide exclusive rights to develop and commercialise drug candidates with antibodies resulting from the collaboration. Memo Therapeutics will receive an upfront payment, research funding during the collaboration period, clinical development and sales milestones, as well as royalties on future sales. The companies did not announce financial details of their transaction.